Prionics Number One in Bovine Tuberculosis Diagnostics Business

Acquisition of Tuberculin Product Line

ZURICH, February 2 - Prionics has acquired the tuberculin business of Lelystad Biologicals
B.V. Through the acquisition, Prionics is now the world's leading provider of
bovine tuberculosis diagnostics.

Bovine tuberculosis (TB) is the most important disease in cattle that can
be spread to humans. Without appropriate control measures bovine TB spreads
quickly as recently seen in Africa, Asia, and in several European countries.
In 2008, over 23,000 outbreaks of the disease were reported in 57 countries,
affecting over 220,000 animals1. To combat the disease, many countries
worldwide have intensified their TB eradication programs. With BOVIGAM(R),
the only validated and OIE2 approved laboratory test for bovine TB, Prionics
is already well established in the TB diagnostics market. Now, Prionics has
extended its bovine TB business by acquiring the tuberculin unit of Lelystad
Biologicals B.V., the leading provider of tuberculin products. "With our
existing laboratory test, BOVIGAM(R), and the new tuberculins that are used
for field testing of bovine TB, Prionics is now able to offer the best
diagnostic test solutions available for the diagnosis of TB in cattle," says
Dr. Markus Moser, CEO of Prionics. "With these products, we can make a
significant contribution to the eradication of this serious zoonotic
disease".

In December 2009, Prionics signed an agreement to purchase the tuberculin
unit of Lelystad Biologicals B.V., a company of Wageningen University and
Research Centre, the Netherlands. The tuberculin product line will contribute
significantly to the financial turnover of the Prionics group.

Tuberculin of highest quality standards

The international reputation of the quality and immunogenic potency of
the Lelystad tuberculin products has been recognized by several customers
including the responsible authorities in the United Kingdom and Ireland. The
Lelystad Biologicals B.V. tuberculin unit, now part of Prionics, has produced
high quality bovine and avian tuberculin PPD3 in its GMP4 approved
manufacturing site in the Netherlands since 1949. The tuberculin production
will be continued in the current production facilities in Lelystad, the
Netherlands. The products are the only tuberculin PPDs that fully comply with
the quality standards described in the European Pharmacopoeia monographs
[0535] and [0536]. These products therefore meet the highest quality
standards and customer requirements. The World Health Organization (WHO)
acknowledged this and approved this tuberculin PPD as the international
standard in 1986.

About Prionics

Prionics AG, based in Zurich, Switzerland, is a leading provider
of farm animal diagnostics and a recognized center of expertise in BSE and
prion diseases. Founded in 1997, Prionics researches and markets innovative
diagnostic solutions for major farm animal diseases, contributing
significantly to the protection of consumer health. Winner of the Swiss
Economic Award for "Company of the year" (2002) and the European Biotech
Award for "Excellence in Biotech Business" (2004), in 2006 Prionics was
nominated as the world's best animal health company in the Animal Pharm
industry excellence awards.

    1 Data compiled by SAFOSO, Berne
    2 OIE: World organization for animal health
    3 PPD: Purified Protein Derivative
    4 GMP: Good Manufacturing Practice

    For more information please visit www.prionics.com/media or
    contact:

    Marjan van der Haar
    Marketing Communications
    Tel: +41-44-200-20-57
    Mobile: +41-79-253-52-16
    Email: media@prionics.com

For more information please visit www.prionics.com/media or contact: Marjan van der Haar, Marketing Communications, Tel: +41-44-200-20-57, Mobile: +41-79-253-52-16, Email: media at prionics.com .